A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects With Cancers of the Head and Neck Receiving Concomitant Chemoradiation Therapy

Trial Profile

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects With Cancers of the Head and Neck Receiving Concomitant Chemoradiation Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs AG 013 (Primary)
  • Indications Stomatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oragenics Inc
  • Most Recent Events

    • 31 Aug 2017 According to an Oragenics media release, first patient has been dosed.
    • 28 Jul 2017 Status changed from planning to recruiting.
    • 18 Apr 2017 According to an Oragenics media release, the company has submitted an IND amendment for this phase II trial. The company has provided the US FDA with the updated protocol for this trial, including the identification of the trial sites in the United States and the manufacturing details of the product material.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top